ACADEMY OF MANAGED CARE PHARMACY for ACADEMY OF MANAGED CARE PHARMACY
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Increased funding for comparative effectiveness research; legislation relating to health information technology and electronic prescribing, appropriations for the U.S. Food and Drug Administration and the Agency for Healthcare Research and Quality
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Medicare/Medicaid MMM
Proposed changes to Medicare Part D prescription drug benefit; modifying current Medicare Part D prompt payment rules for pharmacies in order to better combat fraud, waste and abuse.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Labor Issues/Antitrust/Workplace LBR
Legislation that would grant independent pharmacists collective bargaining rights/antitrust exemption
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Pharmacy PHA
Legislation relating to pharmacy issues and the professional role of pharmacists; legislation relating to medication therapy management programs and funding for such programs, legislation relating to the importation of prescription drugs, legislation relating to settlement agreements between brand-name and generic manufacturers, legislation promoting the use of generic drugs generally, legislation relating to pharmacy benefit managers
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.